Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Revenio: New iCare IC1000 strengthens core business competitiveness

REG1VAnalyst Comment10.09.2026, 10.58
Juha KinnunenAnalyst
Discuss

Summary

  • Revenio has launched the iCare IC1000, a new-generation handheld tonometer, enhancing its core business competitiveness by maintaining technological leadership and market dominance.
  • The iCare IC1000 features improved ease of use and digital workflow support, including a GuideCam for better measurement alignment and a SmartCradle for data integration, aligning with Revenio's strategy towards comprehensive digital solutions.
  • The device is not yet available in the US due to pending FDA approval, which is crucial as the US is considered Revenio's most important market.
  • While traditional tonometer sales growth is slowing, product innovations like the iCare IC1000 are vital for sustaining market position and ongoing probe sales.

This content is generated by AI. You can give feedback on it in the Inderes forum.

Translation: Original published in Finnish on 9/10/2026 at 11:41 am EEST.

On Thursday, Revenio announced the launch of the new-generation handheld iCare IC1000 tonometer. We consider the launch of the new device generation to be a natural and important step in the product development of the company's core business, as it helps the company maintain its technological lead and defend its market leadership. The news is in line with our expectations regarding the company's continuous product development, and the product launch does not cause immediate changes to our forecasts.

New features support workflow digitalization and ease of use

According to the release, the new iCare IC1000 retains the key benefits of the company's rebound technology (RBT), such as being painless, quick, and not requiring anesthesia. The most significant differences from previous models relate to improved ease of use and support for digital workflows. The device features a new GuideCam alignment, which visually guides the user to find the correct measurement position. We believe this feature will further lower the threshold for adopting the device and reduce the variation in measurement results between different users.

In addition, the device was introduced with the new SmartCradle, which, alongside charging the device, enables smoother data transfer and the integration of measurement results into the iCare software ecosystem. In our view, this is a clear indication of the progress of Revenio's strategy: the company aims to move from a mere equipment manufacturer towards more comprehensive digital solutions and seamless care pathways.

Strengthens core business competitiveness, US market still awaits FDA approval

In our estimation, bringing the new device generation to the market is important for Revenio so that the company can maintain the high gross margins of its products and respond to the challenges brought by competitors' RBT technology. Device availability will initially vary by market, and it is not yet on sale in the United States, where the required FDA review process is ongoing. We consider the US to be the company's most important single market, so we are following the progress of the FDA clearance with interest. Overall, we believe the iCare IC1000 is an important addition to the company's product portfolio. Although the growth of device sales in traditional tonometers is slowing down over the longer term, product renewals of this kind are critical to safeguarding a strong market position and continuous probe sales.

 

Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand. In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Read more on company page

Key Estimate Figures09.09

202526e27e
Revenue109.7200.2269.6
growth-%6.0 %82.5 %34.7 %
EBIT (adj.)26.532.244.8
EBIT-% (adj.)24.2 %16.1 %16.6 %
EPS (adj.)0.580.580.64
Dividend0.000.000.00
Dividend %
P/E (adj.)27.715.614.1
EV/EBITDA16.717.710.1

Forum discussions

Message merged into topic: Canatu - Hiilinanoputkikalvojen osaaja
11/18/2026, 11:38 PM
by Sijoittaja-alokas
0
The CEO worked up the courage to make a purchase, but 1,400 shares is almost laughably small for those pay grades: Johdon liiketoimet - Jouni...
11/17/2026, 7:14 AM
by NukkeNukuttaja
19
True, but specifically if you ignore the share price performance, it’s hard to get excited about Revenio. On an earnings basis, the company ...
11/14/2026, 6:14 PM
by JNivala
25
There was a mention of former star companies. Still, the way I see it, risks are often elevated when many valuation metrics are elevated, not...
11/14/2026, 3:37 PM
by WidemoatInvesting
19
Keep in mind, though, that Revenio is a completely different company now. The majority of its current business is lower-margin and a more mixed...
11/14/2026, 12:49 PM
by JNivala
28
The CFO joined our shareholder ranks with an initial investment of €100k: Johdon liiketoimet - Jukka Kainulainen
11/13/2026, 9:04 AM
42
This matter has already been discussed starting from this post, so it might be a bit redundant to share the same link again. Shouldn’t the system...
11/13/2026, 8:01 AM
by NukkeNukuttaja
16